Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) is now available.
Clarity Pharmaceuticals has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for Cu-64 SAR-bisPSMA, expanding its U.S. manufacturing footprint through facilities in Rochester, Minnesota, and a planned large-scale site in Spring House, Pennsylvania. Together, these plants are expected to support production and distribution of Cu-64 SAR-bisPSMA across all 50 U.S. states and select international markets, significantly increasing potential patient access.
The deal deepens Clarity’s existing relationship with Nucleus RadioPharma and complements its broader copper-64 supply and manufacturing network with other partners, positioning the company for a large-scale commercial rollout of Cu-64 SAR-bisPSMA if its Phase III trials succeed and regulatory approvals are obtained. Executives from both firms highlighted the product’s ability, based on existing data, to detect small prostate cancer lesions more effectively than current PSMA PET standards, underscoring its potential to reshape prostate cancer imaging and strengthen Clarity’s competitive standing in radiotheranostics.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$8.41 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on treating serious diseases, primarily cancers, using its Targeted Copper Theranostics based on the SAR Technology Platform. The company develops next-generation radiopharmaceutical products aimed at improving diagnostic accuracy and treatment outcomes for oncology patients in key global markets.
Average Trading Volume: 2,151,541
Technical Sentiment Signal: Sell
Current Market Cap: A$1.18B
Find detailed analytics on CU6 stock on TipRanks’ Stock Analysis page.